Breaking News Instant updates and real-time market news.

BIDU

Baidu

$152.42 /

-0.72 (-0.47%)

05:12
03/01/22
03/01
05:12
03/01/22
05:12

Baidu reports Q4 EPS $1.82, consensus $1.38

Reports Q4 revenue $5.19B, consensus $5.09B. "Baidu concluded a solid 2021, evidenced by a strong growth in our non-advertising business, particularly the acceleration of Baidu AI Cloud. We brought our AI capabilities to China's traditional industries and public service sector, to aid in the improvement of their efficiency and operational expansion. Furthermore, Apollo Go provided around 213,000 rides in the fourth quarter, almost doubling sequentially, reaffirming our leadership position in the global autonomous ride-hailing market," said Robin Li, Co-founder and CEO of Baidu. "Our strategic commitments are closely geared with China's endeavors in technology innovation and transition to a green economy."

  • 01

    Mar

  • 26

    Mar

OTHER BREAKING NEWS FROM THE FLY

Conference/Events
JPMorgan business/info services analysts holds analyst/industry conference call » 22:45
10/06/22
10/06
22:45
10/06/22
22:45
SPGI

S&P Global

$316.03 /

-5.14 (-1.60%)

, MSCI

MSCI

$436.64 /

-11.11 (-2.48%)

, MCO

Moody's

$254.20 /

-7.685 (-2.93%)

, MORN

Morningstar

$224.15 /

-0.87 (-0.39%)

Business and Information…

Business and Information Services Analysts Steineman and Yee discuss trends, market sizing and competitive landscape of the ESG data and research industry on an Analyst/Industry conference call to be held on October 7 at 10:30 am.

ShowHide Related Items >><<
SPGI S&P Global
$316.03 /

-5.14 (-1.60%)

MSCI MSCI
$436.64 /

-11.11 (-2.48%)

MORN Morningstar
$224.15 /

-0.87 (-0.39%)

MCO Moody's
$254.20 /

-7.685 (-2.93%)

SPGI S&P Global
$316.03 /

-5.14 (-1.60%)

08/29/22 Oppenheimer
S&P Global price target raised to $419 from $404 at Oppenheimer
08/03/22 BMO Capital
S&P Global price target raised to $405 from $365 at BMO Capital
07/12/22 Raymond James
S&P Global price target lowered to $417 from $462 at Raymond James
06/08/22 Atlantic Equities
S&P Global price target lowered to $375 from $440 at Atlantic Equities
MSCI MSCI
$436.64 /

-11.11 (-2.48%)

08/16/22 Oppenheimer
MSCI price target raised to $535 from $507 at Oppenheimer
08/10/22 Deutsche Bank
MSCI price target raised to $513 from $478 at Deutsche Bank
07/15/22 Raymond James
MSCI price target lowered to $493 from $515 at Raymond James
06/28/22 RBC Capital
MSCI price target lowered to $520 from $600 at RBC Capital
MCO Moody's
$254.20 /

-7.685 (-2.93%)

08/19/22 Oppenheimer
Moody's price target raised to $348 from $313 at Oppenheimer
08/15/22 BMO Capital
Moody's price target raised to $352 from $309 at BMO Capital
08/10/22 Deutsche Bank
Moody's downgraded to Hold on valuation at Deutsche Bank
08/10/22 Deutsche Bank
Moody's downgraded to Hold from Buy at Deutsche Bank
MORN Morningstar
$224.15 /

-0.87 (-0.39%)

09/20/22 Redburn
Morningstar upgraded to Buy at Redburn on downturn resilience
09/20/22 Redburn
Morningstar upgraded to Buy from Neutral at Redburn
SPGI S&P Global
$316.03 /

-5.14 (-1.60%)

MSCI MSCI
$436.64 /

-11.11 (-2.48%)

MCO Moody's
$254.20 /

-7.685 (-2.93%)

SPGI S&P Global
$316.03 /

-5.14 (-1.60%)

MORN Morningstar
$224.15 /

-0.87 (-0.39%)

MCO Moody's
$254.20 /

-7.685 (-2.93%)

Conference/Events
JPMorgan airfreight analyst to hold an analyst/industry conference call » 22:42
10/06/22
10/06
22:42
10/06/22
22:42

Airfreight & Surface…

Airfreight & Surface Transportation Analyst Ossenbeck, along with EVP De Muynck of project44, provide insights into the post-pandemic supply chain on an Analyst/Industry conference call to be held on October 7 at 10 am.

Recommendations
UnitedHealth policy update 'disappointment' for Nevro, says Piper Sandler » 21:29
10/06/22
10/06
21:29
10/06/22
21:29
NVRO

Nevro

$43.49 /

-5.59 (-11.39%)

, UNH

UnitedHealth

$519.16 /

-7.4 (-1.41%)

UnitedHealth (UNH)…

UnitedHealth (UNH) recently published an updated coverage policy document on spinal cord stimulation devices and their use in non-surgical refractory back pain patients, deeming their use as "unproven and not medically necessary" due to a lack of clinical evidence, Piper Sandler analyst Adam Maeder tells investors in a research note. The analyst says the update comes as a surprise and is a "disappointment" to Nevro (NVRO) shareholders given that the opportunity in non-surgical refractory back pain patients is viewed "as an important pillar to future growth." Maeder estimates this could put about $10M of next year's sales at risk and he maintains a Neutral rating on Nevro shares.

ShowHide Related Items >><<
UNH UnitedHealth
$519.16 /

-7.4 (-1.41%)

NVRO Nevro
$43.49 /

-5.59 (-11.39%)

NVRO Nevro
$43.49 /

-5.59 (-11.39%)

10/06/22 Truist
UnitedHealth policy update 'raises concerns' for Nevro, says Truist
10/05/22 Citi
Citi lowers Nevro target, opens 'negative catalyst watch'
10/03/22 Piper Sandler
AACE guideline update positive for Nevro, says Piper Sandler
09/01/22 Piper Sandler
Piper stays on sidelines of Nevro despite 'handful of positive updates'
UNH UnitedHealth
$519.16 /

-7.4 (-1.41%)

09/22/22 Raymond James
UnitedHealth price target raised to $635 from $620 at Raymond James
09/20/22 Citi
Change Healthcare downgraded to Neutral from Buy at Citi
09/20/22 Piper Sandler
Change Healthcare downgraded to Neutral from Overweight at Piper Sandler
UNH UnitedHealth
$519.16 /

-7.4 (-1.41%)

NVRO Nevro
$43.49 /

-5.59 (-11.39%)

UNH UnitedHealth
$519.16 /

-7.4 (-1.41%)

UNH UnitedHealth
$519.16 /

-7.4 (-1.41%)

NVRO Nevro
$43.49 /

-5.59 (-11.39%)

UNH UnitedHealth
$519.16 /

-7.4 (-1.41%)

Hot Stocks
Alnylam announces FDA approval of Oxlumo in primary hyperoxaluria » 20:35
10/06/22
10/06
20:35
10/06/22
20:35
ALNY

Alnylam

$202.42 /

+1.435 (+0.71%)

Alnylam "announced…

Alnylam "announced that the FDA approved a label expansion for OXLUMO, lumasiran, an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients. The approval is based on positive efficacy and safety results of the ILLUMINATE-C Phase 3 study of OXLUMO in patients with severe renal impairment, including those on hemodialysis. The FDA approval is based on positive six-month results from the ILLUMINATE-C Phase 3 study, in which OXLUMO treatment resulted in substantial reductions in POx and demonstrated an encouraging safety and tolerability profile in patients with compromised renal function, including those with kidney failure and undergoing treatment by hemodialysis. Elevated POx is directly related to the pathophysiology of oxalosis and results in systemic deposition of oxalate in extra-renal tissues, potentially leading to bone fractures, cardiomyopathy, impaired erythropoiesis, vision loss, skin ulcers and other serious manifestations."

ShowHide Related Items >><<
ALNY Alnylam
$202.42 /

+1.435 (+0.71%)

ALNY Alnylam
$202.42 /

+1.435 (+0.71%)

10/03/22 Jefferies
Alnylam price target raised to $232 from $218 at Jefferies
10/03/22 Citi
Alnylam update supports approvability of Onpattro, says Citi
09/20/22 RBC Capital
Alnylam price target raised to $250 from $225 at RBC Capital
09/20/22 Citi
Citi opens 'upside catalyst watch' on Alnylam Pharmaceuticals
ALNY Alnylam
$202.42 /

+1.435 (+0.71%)

ALNY Alnylam
$202.42 /

+1.435 (+0.71%)

Hot Stocks
Tesla's Musk says to make first Semi Truck deliveries to Pepsi on December 1 » 20:19
10/06/22
10/06
20:19
10/06/22
20:19
TSLA

Tesla

$238.14 /

-2.46 (-1.02%)

, PEP

PepsiCo

$162.78 /

-3.3 (-1.99%)

Tesla (TSLA) CEO Elon…

Tesla (TSLA) CEO Elon Musk tweeted: "Excited to announce start of production of Tesla Semi Truck with deliveries to @Pepsi (PEP) on Dec 1st!" Reference Link

ShowHide Related Items >><<
TSLA Tesla
$238.14 /

-2.46 (-1.02%)

PEP PepsiCo
$162.78 /

-3.3 (-1.99%)

TSLA Tesla
$238.14 /

-2.46 (-1.02%)

10/06/22 Mizuho
Tesla price target lowered to $370 from $391.67 at Mizuho
10/05/22 Gordon Haskett
Musk has more Tesla to sell for Twitter deal, says Gordon Haskett
10/04/22 Morgan Stanley
Morgan Stanley expects Tesla shares to give back recent relative strength
10/03/22 JPMorgan
Tesla price target raised to $153 from $137 at JPMorgan
PEP PepsiCo
$162.78 /

-3.3 (-1.99%)

09/30/22 JPMorgan
PepsiCo price target lowered to $186 from $188 at JPMorgan
09/27/22 Deutsche Bank
PepsiCo price target raised to $181 from $179 at Deutsche Bank
08/22/22 Morgan Stanley
Topline momentum building at PepsiCo, says Morgan Stanley
08/19/22 Jefferies
Jefferies concerned about potential Keurig acquisition of Vital
TSLA Tesla
$238.14 /

-2.46 (-1.02%)

PEP PepsiCo
$162.78 /

-3.3 (-1.99%)

TSLA Tesla
$238.14 /

-2.46 (-1.02%)

PEP PepsiCo
$162.78 /

-3.3 (-1.99%)

TSLA Tesla
$238.14 /

-2.46 (-1.02%)

PEP PepsiCo
$162.78 /

-3.3 (-1.99%)

TSLA Tesla
$238.14 /

-2.46 (-1.02%)

PEP PepsiCo
$162.78 /

-3.3 (-1.99%)

Hot Stocks
Cathie Wood's ARK Investment bought 94K shares of Rocket Lab today  20:06
10/06/22
10/06
20:06
10/06/22
20:06
RKLB

Rocket Lab

$4.62 /

+ (+0.00%)

 
ShowHide Related Items >><<
RKLB Rocket Lab
$4.62 /

+ (+0.00%)

RKLB Rocket Lab
$4.62 /

+ (+0.00%)

09/13/22 Deutsche Bank
Rocket Lab named short-term idea at Deutsche Bank
08/31/22 Cowen
Rocket Lab upgraded to Outperform from Market Perform at Cowen
08/17/22 Stifel
Rocket Lab price target lowered to $15 from $18 at Stifel
08/15/22 Deutsche Bank
Rocket Lab price target raised to $15 from $14 at Deutsche Bank
RKLB Rocket Lab
$4.62 /

+ (+0.00%)

RKLB Rocket Lab
$4.62 /

+ (+0.00%)

RKLB Rocket Lab
$4.62 /

+ (+0.00%)

RKLB Rocket Lab
$4.62 /

+ (+0.00%)

Hot Stocks
Cathie Wood's ARK Investment bought 951K shares of Ginkgo Bioworks today  20:05
10/06/22
10/06
20:05
10/06/22
20:05
DNA

Ginkgo Bioworks

$3.23 /

-0.085 (-2.56%)

 
ShowHide Related Items >><<
DNA Ginkgo Bioworks
$3.23 /

-0.085 (-2.56%)

DNA Ginkgo Bioworks
$3.23 /

-0.085 (-2.56%)

10/04/22 Morgan Stanley
Ginkgo Bioworks initiated with an Equal Weight at Morgan Stanley
08/16/22 BTIG
Ginkgo Bioworks price target raised to $6 from $5 at BTIG
08/16/22 Raymond James
Ginkgo Bioworks price target raised to $14.50 from $11.50 at Raymond James
07/26/22 William Blair
Zymergen buyout deal 'best case scenario,' says William Blair
DNA Ginkgo Bioworks
$3.23 /

-0.085 (-2.56%)

DNA Ginkgo Bioworks
$3.23 /

-0.085 (-2.56%)

DNA Ginkgo Bioworks
$3.23 /

-0.085 (-2.56%)

Hot Stocks
Merck, Ridgeback Biotherapeutics provide update on studies of Lagevrio » 19:54
10/06/22
10/06
19:54
10/06/22
19:54
MRK

Merck

$87.43 /

-0.97 (-1.10%)

Merck and Ridgeback…

Merck and Ridgeback Biotherapeutics "issued the following announcement regarding data from two real-world evidence studies evaluating LAGEVRIO, or molnupiravir, an investigational oral antiviral COVID-19 medicine. The first study, PANORAMIC, was conducted by the University of Oxford in the UK in highly-vaccinated adults mostly less than age 65 during the period when the circulating SARS-CoV-2 variant was predominantly Omicron. The second study, Clalit, was conducted by investigators in Israel in mostly older adults with underlying chronic health conditions that make them vulnerable to severe COVID-19 disease, also when Omicron was the most dominant strain. The PANORAMIC pre-print was published today and the Clalit pre-print was published last week. Additionally, Merck is reporting results from a recent carcinogenicity study in transgenic mice, which demonstrated that LAGEVRIO was not carcinogenic at any dose tested. The PANORAMIC study, a UK-based clinical trial sponsored by the University of Oxford, included 25,783 participants who were randomized to open label treatment with LAGEVRIO plus usual care or usual care alone; mean age of participants was 56.6 years. Primary outcome data were available in 25,000 participants. Nearly all participants were vaccinated, with approximately 95% receiving three or more doses of a SARS-CoV-2 vaccine. In the preliminary analysis, the primary endpoint of reduction of hospitalizations and deaths within 28 days of randomization, compared to usual care, was not met; 0.8% of patients in both the LAGEVRIO group and the usual care group were hospitalized or died in the first 28 days. On secondary objectives, LAGEVRIO was associated with improvement on a range of measures compared to usual care. The observed median time to first self-reported recovery was 6 days shorter in the LAGEVRIO group; the median time to first recovery was 9 days on LAGEVRIO vs. 15 days on usual care (range 7 to not reached). Following adjustment for age and baseline comorbidity, there was a substantial estimated improvement of 4 days in time-to-first recovery in the LAGEVRIO group vs. usual care group. The finding on time-to-first recovery was consistent for LAGEVRIO across key subgroups. Secondary objectives were not adjusted for multiplicity. Results from the Clalit study: In this observational, retrospective cohort study, LAGEVRIO was associated with a lower rate of hospitalizations and mortality due to COVID-19 in patients 65 years and above, but not in younger adults. In patients 65 years of age and above, hospitalizations related to COVID-19, the primary endpoint, occurred in 18 LAGEVRIO-treated patients and in 513 untreated patients; adjusted hazard ratio for hospitalization was 0.55. The secondary endpoint of death due to COVID-19 in this same age group occurred in 4 of 845 LAGEVRIO-treated and 137 of 12,724 untreated patients; adjusted HR&#61;0.26. In patients 40 to 64 years of age, hospitalizations related to COVID-19, the primary endpoint, occurred in 8 treated patients and 97 untreated patients , and adjusted HR for hospitalization was 1.80. The secondary endpoint of death due to COVID-19 in this same age group occurred in 4 of 224 LAGEVRIO-treated and 7 of 6,075 untreated patients; adjusted HR&#61;12.82. All four deaths in the LAGEVRIO-treated group occurred in patients 60-64 years of age."

ShowHide Related Items >><<
MRK Merck
$87.43 /

-0.97 (-1.10%)

MRK Merck
$87.43 /

-0.97 (-1.10%)

09/20/22 Piper Sandler
Piper says Merck partial hold being lifted a positive update for Gilead
09/14/22 Berenberg
Merck upgraded to Buy from Hold at Berenberg
08/25/22 Erste Group
Merck upgraded to Buy from Hold at Erste Group
08/18/22 Wells Fargo
Sutro Biopharma assumed with an Overweight at Wells Fargo
MRK Merck
$87.43 /

-0.97 (-1.10%)

MRK Merck
$87.43 /

-0.97 (-1.10%)

MRK Merck
$87.43 /

-0.97 (-1.10%)

MRK Merck
$87.43 /

-0.97 (-1.10%)

Hot Stocks
Infrastructure & Energy Alternatives Inc trading halted, news pending  19:50
10/06/22
10/06
19:50
10/06/22
19:50
IEA

Infrastructure and Energy Alternatives

$13.74 /

-0.025 (-0.18%)

 
ShowHide Related Items >><<
IEA Infrastructure and Energy Alternatives
$13.74 /

-0.025 (-0.18%)

IEA Infrastructure and Energy Alternatives
$13.74 /

-0.025 (-0.18%)

08/08/22 Craig-Hallum
MasTec price target raised to $97 from $87 at Craig-Hallum
07/26/22 Guggenheim
Infrastructure and Energy Alternatives downgraded to Neutral at Guggenheim
07/26/22 Craig-Hallum
MasTec price target lowered to $87 from $108 at Craig-Hallum
07/26/22 DA Davidson
Infrastructure and Energy Alternatives downgraded to Neutral from Buy at DA Davidson
IEA Infrastructure and Energy Alternatives
$13.74 /

-0.025 (-0.18%)

IEA Infrastructure and Energy Alternatives
$13.74 /

-0.025 (-0.18%)

Earnings
Samsung sees Q3 operating profit KRW10.8T vs. KRW12.1T consensus » 19:37
10/06/22
10/06
19:37
10/06/22
19:37
SSNLF

Samsung

$40.60 /

+ (+0.00%)

Sees Q3 revenue KRW76.0T,…

Sees Q3 revenue KRW76.0T, consensus KRW78.5T. Consensus estimates are according to Bloomberg.

ShowHide Related Items >><<
SSNLF Samsung
$40.60 /

+ (+0.00%)

SSNLF Samsung
$40.60 /

+ (+0.00%)

08/22/22 Loop Capital
Enovix price target raised to $100 from $50 at Loop Capital
08/11/22 Loop Capital
Loop Capital has 'stronger conviction' in Enovix after 'customer milestones'
06/22/22 Loop Capital
Samsung initiated with a Buy at Loop Capital
06/13/22 KeyBanc
Qualcomm price target raised to $220 from $200 at KeyBanc
SSNLF Samsung
$40.60 /

+ (+0.00%)

SSNLF Samsung
$40.60 /

+ (+0.00%)

SSNLF Samsung
$40.60 /

+ (+0.00%)

Hot Stocks
Biohaven Pharmaceutical CEO buys $5.0M in common stock » 19:35
10/06/22
10/06
19:35
10/06/22
19:35
BHVN

Biohaven Pharmaceutical

$13.24 /

+0.98 (+7.99%)

In a regulatory filing,…

In a regulatory filing, Biohaven Pharmaceutical disclosed that its CEO Vlad Coric bought 486K shares of common stock on October 5th in a total transaction size of $5.0M.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$13.24 /

+0.98 (+7.99%)

BHVN Biohaven Pharmaceutical
$13.24 /

+0.98 (+7.99%)

08/18/22 Piper Sandler
Biohaven downgraded to Neutral from Overweight at Piper Sandler
08/08/22 Wedbush
Wedbush downgrades Biohaven to Neutral, sees Pfizer acquisition on track
08/08/22 Wedbush
Biohaven Pharmaceutical downgraded to Neutral from Outperform at Wedbush
05/23/22 Piper Sandler
Biohaven price target lowered to $149 from $170 at Piper Sandler
BHVN Biohaven Pharmaceutical
$13.24 /

+0.98 (+7.99%)

BHVN Biohaven Pharmaceutical
$13.24 /

+0.98 (+7.99%)

Hot Stocks
BioNTech to establish mRNA research/manufacturing facility in Victoria » 19:34
10/06/22
10/06
19:34
10/06/22
19:34
BNTX

BioNTech

$137.54 /

+0.295 (+0.21%)

BioNTech "announced…

BioNTech "announced that it has agreed a Letter of Intent with the State of Victoria in Australia on a strategic partnership between the State and BioNTech to collaborate on the research and development of potential mRNA-based vaccines and therapies. As part of the partnership, the parties will establish a research and innovation center in Melbourne to facilitate the transition of encouraging academic research into clinical development. BioNTech plans to set up a clinical scale end-to-end mRNA manufacturing facility based on its BioNTainer solution in Melbourne with the aim of supporting the design, manufacture and clinical testing of product candidates. Part of BioNTech's global network, the facility is expected to attract interest from researchers locally, regionally and globally."

ShowHide Related Items >><<
BNTX BioNTech
$137.54 /

+0.295 (+0.21%)

BNTX BioNTech
$137.54 /

+0.295 (+0.21%)

09/07/22 Deutsche Bank
Moderna upgraded to Buy with $165 target at Deutsche Bank
09/02/22 Cantor Fitzgerald
Cantor says ACIP recommendations support 'continued tail' for COVID-19 vaccines
08/17/22 Cowen
BioNTech initiated with a Market Perform at Cowen
08/10/22 H.C. Wainwright
BioNTech price target lowered to $272 from $283 at H.C. Wainwright
BNTX BioNTech
$137.54 /

+0.295 (+0.21%)

BNTX BioNTech
$137.54 /

+0.295 (+0.21%)

BNTX BioNTech
$137.54 /

+0.295 (+0.21%)

BNTX BioNTech
$137.54 /

+0.295 (+0.21%)

Downgrade
home24 downgraded to Hold from Buy at Jefferies » 19:21
10/06/22
10/06
19:21
10/06/22
19:21
HMAGF

home24

$7.31 /

+3.5374 (+93.83%)

Jefferies analyst Henrik…

Jefferies analyst Henrik Paganetty downgraded home24 to Hold from Buy with a price target of EUR 7.50, up from EUR 4.50. The offer by XXXLutz represents a good deal for H24 shareholders in difficult times, the analyst tells investors in a research note, stating that XXXLutz and H24 are a good strategic fit as both companies have a curated assortment for the mass market.

ShowHide Related Items >><<
HMAGF home24
$7.31 /

+3.5374 (+93.83%)

HMAGF home24
$7.31 /

+3.5374 (+93.83%)

07/18/22 Berenberg
home24 downgraded to Hold from Buy at Berenberg
04/20/22 Berenberg
home24 price target lowered to EUR 9.20 from EUR 15.90 at Berenberg
11/16/21 Jefferies
home24 initiated with a Buy at Jefferies
Hot Stocks
BioMarin redesigns organization, will lay off about 4% of its workforce » 19:02
10/06/22
10/06
19:02
10/06/22
19:02
BMRN

BioMarin

$91.50 /

+1.97 (+2.20%)

BioMarin Pharmaceutical…

BioMarin Pharmaceutical announced its decision to redesign the organization to better focus investments that advance its R&D pipeline, maximize recent commercial launch success, prepare for a potential launch of ROCTAVIAN in the U.S., and drive core infrastructure optimization. This redesign simplifies the organization, creates efficiencies, reduces the average management layers across the organization and prioritizes and heightens the capabilities required to achieve critical business needs of the future. As a result, this decision will involve a reduction in force of approximately 120 employees, or roughly four percent of the global workforce. "We want to recognize everyone impacted by this initiative for their contributions on behalf of the patients we serve. Change is necessary to fulfill our commitment to operating the business in the best interest of our patients, shareholders, and other stakeholders. This requires that our organization is the right size, has the right structure, and has the right focus to operate with maximum effectiveness and efficiency," said Jean-Jacques Bienaime, Chairman and CEO of BioMarin. "This change allows us to continue building upon our core strength in genetic discovery to have a transformative impact on the lives of even more patients." While the focus of the effort was reshaping the organization for operational effectiveness and efficiency, the reduction in force will result in financial savings of approximately $50 million annually beginning in 2023. Management expects to reinvest a significant portion of the savings in BioMarin's clinical development portfolio, early-stage pipeline, and Roctavian and Voxzogo launches, while the remainder will contribute to the Company's goal of increasing profitability and expanding operating margins. Impacted employees have been notified as of this week, and they have begun the transition process that will be fully supported by the Company. Most of the reduction will come from BioMarin's U.S. operations and the reductions are expected to be substantially completed by December 31, 2022. As a result of the reduction in force, the Company will incur total estimated pre-tax charges of approximately $20 - $25 million spread across the third and fourth quarters of 2022, representing one-time cash expenditures for severance and employee termination benefits.

ShowHide Related Items >><<
BMRN BioMarin
$91.50 /

+1.97 (+2.20%)

BMRN BioMarin
$91.50 /

+1.97 (+2.20%)

09/28/22 Stifel
BioMarin price target raised to $104 after model adjustments at Stifel
09/13/22 Morgan Stanley
Morgan Stanley sees Roctavian approval, but says B-ALL case adds uncertainty
09/12/22 Piper Sandler
BioMarin should be bought on weakness, says Piper Sandler
09/12/22 Truist
Truist 'defending' BioMarin after Phase 3 patient diagnosed with B-cell ALL
BMRN BioMarin
$91.50 /

+1.97 (+2.20%)

BMRN BioMarin
$91.50 /

+1.97 (+2.20%)

Recommendations
AMD price target lowered to $90 from $140 at Piper Sandler » 18:40
10/06/22
10/06
18:40
10/06/22
18:40
AMD

AMD

$67.85 /

-0.02 (-0.03%)

Piper Sandler analyst…

Piper Sandler analyst Harsh Kumar lowered the firm's price target on AMD to $90 from $140 and keeps an Overweight rating on the shares after the company revised estimates for the September quarter. Kumar noted that roughly $1B of the revenue decrease in the new expectation relates to decline in the PC segment, which has been cut in half from about $2B to roughly $1B. The analyst noted that data center, which he and investors care about "much more," managed to grow to $1.6B, and is off roughly $100M relative to previous expectations.

ShowHide Related Items >><<
AMD AMD
$67.85 /

-0.02 (-0.03%)

AMD AMD
$67.85 /

-0.02 (-0.03%)

10/05/22 Wells Fargo
AMD price target lowered to $90 from $130 at Wells Fargo
09/23/22 Morgan Stanley
AMD price target lowered to $95 from $102 at Morgan Stanley
09/15/22 Wedbush
AMD removed from Best Ideas List at Wedbush
09/15/22 Mizuho
AMD price target lowered to $125 from $140 at Mizuho
AMD AMD
$67.85 /

-0.02 (-0.03%)

AMD AMD
$67.85 /

-0.02 (-0.03%)

AMD AMD
$67.85 /

-0.02 (-0.03%)

AMD AMD
$67.85 /

-0.02 (-0.03%)

Hot Stocks
Constellation Brands CEO: We see great consumer demand » 18:23
10/06/22
10/06
18:23
10/06/22
18:23
STZ

Constellation Brands

$232.47 /

-3.37 (-1.43%)

In an interview on…

In an interview on CNBC's Mad Money, Bill Newlands said the amount of growth Constellation Brands is seeing is "unprecedented." The business excelled in almost every dimension in the beer category, he noted. The company is investing in higher growth, higher margin businesses. Newlands is "very confident" that Constellation will have a strong year.

ShowHide Related Items >><<
STZ Constellation Brands
$232.47 /

-3.37 (-1.43%)

STZ Constellation Brands
$232.47 /

-3.37 (-1.43%)

09/30/22 Barclays
Constellation Brands price target lowered to $272 from $284 at Barclays
09/29/22 Credit Suisse
Constellation Brands price target lowered to $277 from $292 at Credit Suisse
09/15/22 JPMorgan
Constellation Brands price target raised to $287 from $263 at JPMorgan
08/02/22 BMO Capital
Constellation Brands initiated with an Outperform at BMO Capital
STZ Constellation Brands
$232.47 /

-3.37 (-1.43%)

STZ Constellation Brands
$232.47 /

-3.37 (-1.43%)

STZ Constellation Brands
$232.47 /

-3.37 (-1.43%)

STZ Constellation Brands
$232.47 /

-3.37 (-1.43%)

Periodicals
Twitter says it looks forward to closing Musk buyout by Oct 28, Bloomberg says » 18:21
10/06/22
10/06
18:21
10/06/22
18:21
TWTR

Twitter

$49.44 /

-1.86 (-3.63%)

, TSLA

Tesla

$238.14 /

-2.46 (-1.02%)

Twitter (TWTR) said it…

Twitter (TWTR) said it looks forward to closing its buyout deal with Tesla (TSLA) CEO Elon Musk by October 28 at $54.20 per share, according to Bloomberg.

ShowHide Related Items >><<
TWTR Twitter
$49.44 /

-1.86 (-3.63%)

TSLA Tesla
$238.14 /

-2.46 (-1.02%)

TWTR Twitter
$49.44 /

-1.86 (-3.63%)

10/06/22 Wedbush
Twitter Board playing game of high stakes poker, says Wedbush
10/05/22 Gordon Haskett
Musk has more Tesla to sell for Twitter deal, says Gordon Haskett
10/05/22 Vertical Group
Twitter downgraded to Neutral from Buy at Vertical Group
10/05/22 Citi
Citi ups Twitter target to $54.20, says takeover likely to close
TSLA Tesla
$238.14 /

-2.46 (-1.02%)

10/06/22 Mizuho
Tesla price target lowered to $370 from $391.67 at Mizuho
10/04/22 Morgan Stanley
Morgan Stanley expects Tesla shares to give back recent relative strength
10/03/22 JPMorgan
Tesla price target raised to $153 from $137 at JPMorgan
TWTR Twitter
$49.44 /

-1.86 (-3.63%)

TSLA Tesla
$238.14 /

-2.46 (-1.02%)

TWTR Twitter
$49.44 /

-1.86 (-3.63%)

TWTR Twitter
$49.44 /

-1.86 (-3.63%)

TWTR Twitter
$49.44 /

-1.86 (-3.63%)

TSLA Tesla
$238.14 /

-2.46 (-1.02%)

On The Fly
Fly Intel: After-Hours Movers » 18:16
10/06/22
10/06
18:16
10/06/22
18:16
AEHR

Aehr Test Systems

$13.90 /

-0.435 (-3.04%)

, ACCD

Accolade

$12.34 /

-0.14 (-1.12%)

, ALLO

Allogene Therapeutics

$10.98 /

+0.19 (+1.76%)

, DKNG

DraftKings

$16.03 /

-0.66 (-3.95%)

, DIS

Disney

$100.05 /

-0.71 (-0.70%)

, LYEL

Lyell Immunopharma

$8.08 /

+0.135 (+1.70%)

, PAYO

Payoneer Global

$7.07 /

+0.215 (+3.14%)

, GFF

Griffon

$31.47 /

-0.48 (-1.50%)

, MSGS

MSG Sports

$140.50 /

-2 (-1.40%)

, LEVI

Levi Strauss

$15.91 /

-0.68 (-4.10%)

, AMD

AMD

$67.85 /

-0.02 (-0.03%)

, NVDA

Nvidia

$131.30 /

-0.76 (-0.58%)

, LNTH

Lantheus

$74.69 /

-2.83 (-3.65%)

, CVS

CVS Health

$98.57 /

-1.88 (-1.87%)

Check out this evening's…

ShowHide Related Items >><<
PAYO Payoneer Global
$7.07 /

+0.215 (+3.14%)

NVDA Nvidia
$131.30 /

-0.76 (-0.58%)

MSGS MSG Sports
$140.50 /

-2 (-1.40%)

LYEL Lyell Immunopharma
$8.08 /

+0.135 (+1.70%)

LNTH Lantheus
$74.69 /

-2.83 (-3.65%)

LEVI Levi Strauss
$15.91 /

-0.68 (-4.10%)

GFF Griffon
$31.47 /

-0.48 (-1.50%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DIS Disney
$100.05 /

-0.71 (-0.70%)

CVS CVS Health
$98.57 /

-1.88 (-1.87%)

AMD AMD
$67.85 /

-0.02 (-0.03%)

ALLO Allogene Therapeutics
$10.98 /

+0.19 (+1.76%)

AEHR Aehr Test Systems
$13.90 /

-0.435 (-3.04%)

ACCD Accolade
$12.34 /

-0.14 (-1.12%)

AEHR Aehr Test Systems
$13.90 /

-0.435 (-3.04%)

10/08/21 Craig-Hallum
Aehr Test Systems price target raised to $31 from $12 at Craig-Hallum
ACCD Accolade
$12.34 /

-0.14 (-1.12%)

10/04/22 Needham
Accolade price target raised to $15 from $12 at Needham
10/04/22 Piper Sandler
Accolade positioning intact despite Comcast termination, says Piper Sandler
10/03/22 Canaccord
Accolade price target raised to $15 from $12 at Canaccord
09/08/22 Piper Sandler
Accolade assumed with an Overweight at Piper Sandler
ALLO Allogene Therapeutics
$10.98 /

+0.19 (+1.76%)

09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
08/10/22 Oppenheimer
Allogene Therapeutics price target lowered to $35 from $40 at Oppenheimer
DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

10/06/22 Exane BNP Paribas
DraftKings initiated with an Underperform at Exane BNP Paribas
09/14/22 Oppenheimer
TNF sponsorship key step to generating higher SGP adoption, says Oppenheimer
09/14/22 Guggenheim
DraftKings price target raised to $34 from $31 at Guggenheim
09/06/22 Susquehanna
DraftKings price target raised to $24 from $20 at Susquehanna
DIS Disney
$100.05 /

-0.71 (-0.70%)

10/04/22 JPMorgan
Disney price target lowered to $145 from $160 at JPMorgan
09/30/22 BofA
Disney price target lowered to $127 from $144 at BofA
09/26/22 Evercore ISI
Disney+ ad-supported tier should be accretive to ARPU, says Evercore ISI
09/16/22 Citi
Citi ups Netflix target, says SVOD sentiment will improve
LYEL Lyell Immunopharma
$8.08 /

+0.135 (+1.70%)

PAYO Payoneer Global
$7.07 /

+0.215 (+3.14%)

07/14/22 Goldman Sachs
Payoneer Global upgraded to Buy from Neutral at Goldman Sachs
05/13/22 Northland
Payoneer Global price target lowered to $9 from $14 at Northland
05/13/22 Citi
Payoneer Global price target raised to $7.50 from $6.50 at Citi
03/04/22 Needham
Payoneer Global price target lowered to $7 from $13 at Needham
GFF Griffon
$31.47 /

-0.48 (-1.50%)

09/08/22 Raymond James
Griffon added to 'Analyst Current Favorites' list at Raymond James
05/17/22 Baird
Griffon price target raised to $44 from $40 at Baird
05/16/22 CJS Securities
Griffon break-up value could be $75 per share, says CJS Securities
05/02/22 Raymond James
Griffon upgraded to Strong Buy from Outperform at Raymond James
MSGS MSG Sports
$140.50 /

-2 (-1.40%)

07/05/22 Macquarie
MSG Sports price target lowered to $230 from $240 at Macquarie
06/02/22 Wolfe Research
MSG Sports price target lowered to $231 from $238 at Wolfe Research
12/15/21 Morgan Stanley
MSG Sports downgraded to Equal Weight from Overweight at Morgan Stanley
11/01/21 JPMorgan
MSG Sports price target raised to $220 from $190 at JPMorgan
LEVI Levi Strauss
$15.91 /

-0.68 (-4.10%)

09/16/22 JPMorgan
Levi Strauss price target raised to $23 from $22 at JPMorgan
08/04/22 Morgan Stanley
Levi Strauss downgraded to Equal Weight from Overweight at Morgan Stanley
07/20/22 Stifel
Levi Strauss price target lowered to $23 from $26 at Stifel
07/15/22 UBS
Levi Strauss price target lowered to $24 from $31 at UBS
AMD AMD
$67.85 /

-0.02 (-0.03%)

10/05/22 Wells Fargo
AMD price target lowered to $90 from $130 at Wells Fargo
09/23/22 Morgan Stanley
AMD price target lowered to $95 from $102 at Morgan Stanley
09/15/22 Wedbush
AMD removed from Best Ideas List at Wedbush
09/15/22 Mizuho
AMD price target lowered to $125 from $140 at Mizuho
NVDA Nvidia
$131.30 /

-0.76 (-0.58%)

09/21/22 Morgan Stanley
Morgan Stanley says higher gaming GPU prices biggest takeaway from Nvidia event
09/21/22 BMO Capital
Nvidia price target lowered to $210 from $230 at BMO Capital
09/21/22 Susquehanna
Nvidia price target lowered to $190 from $200 at Susquehanna
09/21/22 Barclays
Nvidia offered little new in terms of announcements, says Barclays
LNTH Lantheus
$74.69 /

-2.83 (-3.65%)

10/06/22 JonesTrading
Lantheus initiated with a Buy at JonesTrading
05/09/22 B. Riley
Lantheus initiated with a Buy at B. Riley
05/09/22 B. Riley
Lantheus initiated with a Buy at B. Riley
05/02/22 Truist
Lantheus price target raised to $94 from $77 at Truist
CVS CVS Health
$98.57 /

-1.88 (-1.87%)

09/23/22 Citi
Cano Health could be worth $14 per share in buyout, says Citi
09/20/22 Piper Sandler
Change Healthcare downgraded to Neutral from Overweight at Piper Sandler
09/07/22 Evercore ISI
CVS Health price target raised to $125 from $120 at Evercore ISI
09/07/22 UBS
Signify Health downgraded to Neutral from Buy at UBS
PAYO Payoneer Global
$7.07 /

+0.215 (+3.14%)

NVDA Nvidia
$131.30 /

-0.76 (-0.58%)

MSGS MSG Sports
$140.50 /

-2 (-1.40%)

LYEL Lyell Immunopharma
$8.08 /

+0.135 (+1.70%)

LNTH Lantheus
$74.69 /

-2.83 (-3.65%)

LEVI Levi Strauss
$15.91 /

-0.68 (-4.10%)

GFF Griffon
$31.47 /

-0.48 (-1.50%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DIS Disney
$100.05 /

-0.71 (-0.70%)

CVS CVS Health
$98.57 /

-1.88 (-1.87%)

AMD AMD
$67.85 /

-0.02 (-0.03%)

ALLO Allogene Therapeutics
$10.98 /

+0.19 (+1.76%)

AEHR Aehr Test Systems
$13.90 /

-0.435 (-3.04%)

ACCD Accolade
$12.34 /

-0.14 (-1.12%)

NVDA Nvidia
$131.30 /

-0.76 (-0.58%)

MSGS MSG Sports
$140.50 /

-2 (-1.40%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DIS Disney
$100.05 /

-0.71 (-0.70%)

CVS CVS Health
$98.57 /

-1.88 (-1.87%)

AMD AMD
$67.85 /

-0.02 (-0.03%)

PAYO Payoneer Global
$7.07 /

+0.215 (+3.14%)

NVDA Nvidia
$131.30 /

-0.76 (-0.58%)

LNTH Lantheus
$74.69 /

-2.83 (-3.65%)

LEVI Levi Strauss
$15.91 /

-0.68 (-4.10%)

GFF Griffon
$31.47 /

-0.48 (-1.50%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DIS Disney
$100.05 /

-0.71 (-0.70%)

CVS CVS Health
$98.57 /

-1.88 (-1.87%)

AMD AMD
$67.85 /

-0.02 (-0.03%)

ALLO Allogene Therapeutics
$10.98 /

+0.19 (+1.76%)

AEHR Aehr Test Systems
$13.90 /

-0.435 (-3.04%)

ACCD Accolade
$12.34 /

-0.14 (-1.12%)

NVDA Nvidia
$131.30 /

-0.76 (-0.58%)

LEVI Levi Strauss
$15.91 /

-0.68 (-4.10%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DIS Disney
$100.05 /

-0.71 (-0.70%)

CVS CVS Health
$98.57 /

-1.88 (-1.87%)

AMD AMD
$67.85 /

-0.02 (-0.03%)

AEHR Aehr Test Systems
$13.90 /

-0.435 (-3.04%)

Periodicals
Walmart to lay off 1,500 workers at Atlanta fulfillment center, Reuters says » 18:15
10/06/22
10/06
18:15
10/06/22
18:15
WMT

Walmart

$131.69 /

-1.165 (-0.88%)

In a Worker Adjustment…

In a Worker Adjustment and Retraining Notification filed on Wednesday, Walmart disclosed that it would lay off 1,458 workers at the e-commerce fulfillment center located in Fulton Parkway in Atlanta, Georgia, Reuters' Siddharth Cavale reports. The report further states that when contacting the company, Reuters learned Walmart was implementing the layoffs at the facility, and that the impacted staff were notified about the layoffs in late August. Reference Link

ShowHide Related Items >><<
WMT Walmart
$131.69 /

-1.165 (-0.88%)

WMT Walmart
$131.69 /

-1.165 (-0.88%)

10/05/22 Erste Group
Walmart upgraded to Buy from Hold at Erste Group
09/14/22 KeyBanc
Walmart initiated with an Overweight at KeyBanc
09/13/22 Maxim
Maxim starts Edible Garden at Buy on consistent produce growth and distribution
09/08/22 Deutsche Bank
UnitedHealth price target raised to $569 from $556 at Deutsche Bank
WMT Walmart
$131.69 /

-1.165 (-0.88%)

WMT Walmart
$131.69 /

-1.165 (-0.88%)

WMT Walmart
$131.69 /

-1.165 (-0.88%)

WMT Walmart
$131.69 /

-1.165 (-0.88%)

Initiation
Kinetik Holdings initiated with a Neutral at Goldman Sachs » 18:08
10/06/22
10/06
18:08
10/06/22
18:08
KNTK

Kinetik Holdings

$36.62 /

+0.215 (+0.59%)

Goldman Sachs analyst…

Goldman Sachs analyst John Mackay initiated coverage of Kinetik Holdings with a Neutral rating and $37 price target. The analyst expects "solid" EBITDA growth from Kinetik as it should benefit next year from tightening Permian processing supply/demand dynamics and strong commodity prices. Mackay also believes medium term expansions require relatively meaningful capex into 2024, which should drive high funding needs.

ShowHide Related Items >><<
KNTK Kinetik Holdings
$36.62 /

+0.215 (+0.59%)

KNTK Kinetik Holdings
$36.62 /

+0.215 (+0.59%)

08/25/22 Morgan Stanley
Kinetik Holdings initiated with an Equal Weight at Morgan Stanley
07/20/22 Mizuho
Kinetik Holdings price target raised to $41 from $39 at Mizuho
05/16/22 Credit Suisse
Kinetik Holdings price target raised to $80 from $72 at Credit Suisse
05/12/22 Mizuho
Kinetik Holdings price target raised to $78 from $76 at Mizuho
KNTK Kinetik Holdings
$36.62 /

+0.215 (+0.59%)

  • 09
    Mar
KNTK Kinetik Holdings
$36.62 /

+0.215 (+0.59%)

Hot Stocks
Teck Resources reports Q3 steelmaking coal sales and pricing » 17:58
10/06/22
10/06
17:58
10/06/22
17:58
TECK

Teck Resources

$32.26 /

-0.57 (-1.74%)

Teck Resources provided…

Teck Resources provided unaudited Q3 steelmaking coal sales of 5.6 million tons, within revised guidance of 5.5-5.9 million tons. Q3 realized steelmaking coal price averaged $304 per ton. The company expects to report negative provisional pricing adjustments of $191M in Q3 due to the decline in steelmaking coal prices during the quarter.

ShowHide Related Items >><<
TECK Teck Resources
$32.26 /

-0.57 (-1.74%)

TECK Teck Resources
$32.26 /

-0.57 (-1.74%)

10/05/22 Deutsche Bank
Teck Resources price target lowered to $42 from $43 at Deutsche Bank
10/03/22 Raymond James
Teck Resources price target lowered to C$54 from C$56 at Raymond James
09/28/22 Jefferies
Jefferies starts Teck Resources at Buy on met coal strength, copper growth
09/28/22 Jefferies
Teck Resources initiated with a Buy at Jefferies
TECK Teck Resources
$32.26 /

-0.57 (-1.74%)

TECK Teck Resources
$32.26 /

-0.57 (-1.74%)

TECK Teck Resources
$32.26 /

-0.57 (-1.74%)

Hot Stocks
NYSE to delist Avanti Acquisition » 17:56
10/06/22
10/06
17:56
10/06/22
17:56
AVAN

Avanti Acquisition

$10.04 /

+0.01 (+0.10%)

The New York Stock…

The New York Stock Exchange "announced that the staff of NYSE Regulation has determined to commence proceedings to delist the three securities enumerated below of Avanti Acquisition Corp. from the Exchange. Trading in the Company's Securities will be suspended immediately."

ShowHide Related Items >><<
AVAN Avanti Acquisition
$10.04 /

+0.01 (+0.10%)

Periodicals
DraftKings, ESPN near signing exclusive deal, Action Network reports » 17:53
10/06/22
10/06
17:53
10/06/22
17:53
DKNG

DraftKings

$16.03 /

-0.66 (-3.95%)

, DIS

Disney

$100.05 /

-0.71 (-0.70%)

DraftKings (DKNG) and…

DraftKings (DKNG) and Disney's (DIS) ESPN are near signing an exclusive partnership, Action Network's Darren Rovell reports, citing sources. ESPN was seeking a partner in hopes of securing $3B over a period of time that would lead to a sportsbook rebranding itself with the ESPN brand, but that's not the case with this deal, as the agreement is a massive exclusive partnership that will have shows and perhaps odds integrated into game broadcasts, Rovell says. Reference Link

ShowHide Related Items >><<
DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DIS Disney
$100.05 /

-0.71 (-0.70%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

10/06/22 Exane BNP Paribas
DraftKings initiated with an Underperform at Exane BNP Paribas
09/14/22 Oppenheimer
TNF sponsorship key step to generating higher SGP adoption, says Oppenheimer
09/14/22 Guggenheim
DraftKings price target raised to $34 from $31 at Guggenheim
09/06/22 Susquehanna
DraftKings price target raised to $24 from $20 at Susquehanna
DIS Disney
$100.05 /

-0.71 (-0.70%)

10/04/22 JPMorgan
Disney price target lowered to $145 from $160 at JPMorgan
09/30/22 BofA
Disney price target lowered to $127 from $144 at BofA
09/26/22 Evercore ISI
Disney+ ad-supported tier should be accretive to ARPU, says Evercore ISI
09/16/22 Citi
Citi ups Netflix target, says SVOD sentiment will improve
DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DIS Disney
$100.05 /

-0.71 (-0.70%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DIS Disney
$100.05 /

-0.71 (-0.70%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DIS Disney
$100.05 /

-0.71 (-0.70%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DIS Disney
$100.05 /

-0.71 (-0.70%)

Hot Stocks
DraftKings jumps 8% to $17.39 after report of a partnership with ESPN  17:36
10/06/22
10/06
17:36
10/06/22
17:36
DKNG

DraftKings

$16.03 /

-0.66 (-3.95%)

 
ShowHide Related Items >><<
DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

10/06/22 Exane BNP Paribas
DraftKings initiated with an Underperform at Exane BNP Paribas
09/14/22 Oppenheimer
TNF sponsorship key step to generating higher SGP adoption, says Oppenheimer
09/14/22 Guggenheim
DraftKings price target raised to $34 from $31 at Guggenheim
09/06/22 Susquehanna
DraftKings price target raised to $24 from $20 at Susquehanna
DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

DKNG DraftKings
$16.03 /

-0.66 (-3.95%)

Hot Stocks
Arco Platform to acquire 75% of INCO Limited, dba isaac » 17:35
10/06/22
10/06
17:35
10/06/22
17:35
ARCE

Arco Platform

$11.84 /

-0.34 (-2.79%)

Arco Platform…

Arco Platform "announced that it has entered into a definitive agreement to acquire 75.1% of the share capital of INCO Limited, d/b/a isaac, the provider of an all-in-one platform that offers a suite of financial and software products to K-12 schools. The purchase price for the Transaction will be paid in the form of Arco equity interests. Prior to the Transaction, Arco already held 24.9% of the issued and outstanding equity interests of isaac."

ShowHide Related Items >><<
ARCE Arco Platform
$11.84 /

-0.34 (-2.79%)

08/30/22 JPMorgan
Arco Platform upgraded to Overweight from Neutral at JPMorgan
08/26/22 Credit Suisse
Arco Platform downgraded to Neutral from Outperform at Credit Suisse
02/16/22 JPMorgan
Arco Platform initiated with a Neutral at JPMorgan
ARCE Arco Platform
$11.84 /

-0.34 (-2.79%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.